HC Wainwright Has Positive View of Urogen Pharma Q2 Earnings

Urogen Pharma (NASDAQ:URGN) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings estimates for Urogen Pharma in a note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.61) per share for the quarter, up from their prior forecast of ($0.64). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.26) EPS and Q2 2027 earnings at ($0.02) EPS.

A number of other equities research analysts have also recently issued reports on URGN. LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research note on Monday. They issued a “buy” rating and a $43.00 price objective on the stock. Oppenheimer boosted their price target on shares of Urogen Pharma from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. Finally, D. Boral Capital restated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and an average target price of $36.67.

Urogen Pharma Price Performance

Shares of URGN opened at $29.80 on Wednesday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $32.37. The stock’s fifty day moving average price is $21.13 and its two-hundred day moving average price is $21.83. The firm has a market cap of $1.45 billion, a PE ratio of -10.84 and a beta of 1.58.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million.

Hedge Funds Weigh In On Urogen Pharma

A number of large investors have recently modified their holdings of URGN. Mirae Asset Global Investments Co. Ltd. increased its stake in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the last quarter. CWM LLC lifted its stake in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after purchasing an additional 650 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC boosted its holdings in shares of Urogen Pharma by 8.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after purchasing an additional 2,125 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.